

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
05 April 2018 (05.04.2018)



(10) International Publication Number
WO 2018/060904 A1

(51) International Patent Classification:

G01N 33/558 (2006.01) G01N 33/576 (2006.01)
G01N 33/573 (2006.01)

(21) International Application Number:

PCT/IB2017/055943

(22) International Filing Date:

28 September 2017 (28.09.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

201610878590.7 30 September 2016 (30.09.2016) CN

(71) Applicant: **NANJING BIOPOINT DIAGNOSTIC TECHNOLOGY CO. LTD** [CN/CN]; JiangSu Life Science and Innovation Park, Room 320, F7, No 9, WeiDi Road, XianLin University Town, QiXia District, Nanjing, Jiangsu (CN).

(72) Inventors: **ANDERSON, David Andrew**; C/-Macfarlane Burnet Institute for Medical Research and Public Health Limited, 85 Commercial Road, Melbourne, Victoria 3004 (AU). **GARCIA, Mary Louise**; C/- Macfarlane Burnet Institute for Medical Research and Public Health Limited, 85 Commercial Road, VIC, Melbourne, Victoria 3004 (AU). **VAN, Huy**; C/- Macfarlane Burnet Institute for Medical Research and Public Health Limited, 85 Commercial Road, Melbourne, 3004 (AU). **ZHANG, Zhimei**; C/-Nanjing Bio-Point Diagnostic Technology Co. Ltd, JiangSu Life Science and Innovation Park, Room 320, F7, No 9, WeiDi Road, XianLin University Town, QiXia District, Nanjing, Jiangsu (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: POINT OF CARE ASSAYS

(57) Abstract: An immunoassay suitable for point of care to assess liver disease or function comprising contacting a blood sample from a subject with a specific binding agent that recognizes an epitope of ALT1, that is not recognized by rodent antibodies when the rodent antibodies are in the presence of human plasma, to form an antigen-binding agent complex and detecting the complex using a second or further binding agent linked to or comprising a detectable reporter; and detecting liver disease or liver function in the subject contingent upon the mass concentration of ALT1 in the sample. Kits or devices comprising lagomorph antibodies or binding agents comprising the antigen binding component thereof suitable for measuring the mass concentration of ALT1 in a blood sample from a subject to determine liver function.



WO 2018/060904 A1